

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**




FIG. 1




FIG. 2




FIG. 3




FIG. 4

500




FIG. 5




FIG. 6



Acme Pharmaceuticals

KDISCOVERER

700

User Name : 702

Password : 704

☒ Remember my user name and password

706

Login

New User

If you forget your password, please call 1-800-PASSWRD.

Copyright (c) 1999 - Andersen Consulting LLP. All rights reserved.

FIG. 7




FIG. 8

Acme Pharmaceuticals **KDISCOVERER - Welcome!** [Edit Profile](#) [Sitemap](#) [Logout](#)

[Recent News](#) [Organizer](#) [Research](#) [Development](#) [Commercialization](#) [Search & Browse](#)

Therapeutic Area : Cardiology/Vascular Diseases

Target

- ◁ Cardiology
 - ◁ Cholesterol
 - ◁ Chronic Occlusive Arterial...
- ◁ Cardiology/Vascular Diseases*
 - ◁ 5-AMP Deaminase*
 - ◁ ACE (Angiotensin-converting Enzyme)*-protein-gated K-...
 - ◁ Angiotensin Receptor*
 - ◁ Antiarrhythmics
 - ◁ Arterial
 - ◁ Branchodilator Agent
 - ◁ Calcium Channel
 - ◁ Coronary
 - ◁ Digitalis Glycosides
 - ◁ Epithelial Sodium Channel*
 - ◁ Ganglionic Blocker
 - ◁ Inotropic Drug
 - ◁ Miscellaneous
 - ◁ Non-Radiopaque Agent
 - ◁ Radiopaque Agent
 - ◁ Selective C-Gmp. Phosphod...
 - ◁ Miscellaneous
 - ◁ Sympatholytic
 - ◁ Vasodilator
 - ◁ Veinotonics/Vasculoprotec...
 - ◁ Venosclerosing Agent
 - ◁ Veratrum Alkaloids
 - ◁ Xanthines

THE BERNIN
For evaluation use only

Therapeutic Area : Cardiology/Vascular Diseases

Quick Search and Browse [Search](#) [Help](#)

Copyright (c) 1999 - Andersen Consulting LLP.




FIG. 10




FIG. 12




FIG. 13





FIG. 14

1600



Monitored Items

Organizations

Merck

Targets

TR27 K-channel

Scientists

Ahiskali R

South Korea

Target

Search

Help

Copyright (c) 1998 - Andersen Consulting LLP.

1604

Organizations

Merck

- FDA: 20560
- FDA: 20685
- Patent 4370829
- Alfuzosin is not associated with dermatomyositis.

Targets

TR27 K-channel

- Patent 4188390

Scientists

Ahiskali R

- The effect of losartan and captopril on glomerular basement membrane anionic charge in a diabetic rat model.

1608

1610

1612

1614

1618

FIG. 16

1620




FIG. 17




FIG. 18A




FIG. 18B




FIG. 18C





FIG. 18D

FIG. 19






FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24




FIG. 25




FIGURE 26